Literature DB >> 9179641

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.

C A Tamminga1, R J Mack, G R Granneman, C J Silber, K B Kashkin.   

Abstract

Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12-24 mg/day. Its action against positive symptoms is as potent as that of the traditional antipsychotic haloperidol. Its action against negative symptoms is significantly different from that of placebo and quantitatively larger than that of haloperidol. Its most distinctive characteristic is a reduction in motor side effects over a whole range of comparable drug and comparator doses. More work is needed to determine whether sertindole's actions against negative symptoms influence the primary or the secondary negative system. There are insufficient data at present to compare sertindole with the highly efficacious drug clozapine or the other new antipsychotic olanzapine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179641     DOI: 10.1097/00004850-199702001-00005

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders.

Authors:  Tilman Steinert; Barbara Hauger; Jürgen Eckardt; Peter Schmid
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 3.  Quetiapine: a review of its safety in the management of schizophrenia.

Authors:  V Dev; J Raniwalla
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 4.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  The newer, 'atypical' antipsychotic drugs--their development and current therapeutic use.

Authors:  T Kendrick
Journal:  Br J Gen Pract       Date:  1999-09       Impact factor: 5.386

6.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 7.  Sertindole for schizophrenia.

Authors:  R Lewis; A-M Bagnall; M Leitner
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

8.  Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Authors:  Michael Didriksen; Torben Skarsfeldt; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2007-04-04       Impact factor: 4.415

9.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.